摘要
Background: The catechol O methyltransferase inhibitor entacaponeacts by exte nding the elimination half life of levodopaand is currently approved as an adju nct to levodopa for thetreatment of patients with Parkinson disease (PD) with mo torfluctuations. Objective: To determine if the addition of entacapone administr ation provides benefit to levodopa treated PD patients who have a stable respon se to levodopa and do notexperience motor complications. Design: Prospective, do ubleblind,placebo controlled trial. Setting: Outpatient multicenter study. Pati ents: Female and male patients 30 years or older with idiopathic PD receiving st able doses of levodopa or carbidopa with or without other dopaminergic therapies and who did not experience motor fluctuations were eligible for the study. Main Outcome Measures: Parkinsonian function and quality of life. Results: The addit ion of entacapone did not improve motor scores on the Unified Parkinsons Disea se Rating Scale in levodopa treated PD patients who did not experience motor fl uctuations. The mean ±SE adjusted change between baseline and final treatment v isitwas -0.9±0.35 in the entacapone group and -0.8 ±0.35 in the placebo grou p (P = .83). Significant improvement with entacapone treatment was detected in s everal quality of life measures, including the Parkinson Disease Questionnaire 39, the 36 item Short Form Health Survey, the Parkinsons Symptom Inventory, and investigator and subject Clinical Global Assessments. The drug was well tolerated by patients in this population . Conclusions: The catechol Omethyltransferase inhibitor entacapone, used as an adjunct to levodopa in PD patients who do not experience motor fluctuations, doe s not improve Unified Parkinsons Disease Rating Scale motor scores but does im prove a variety of quality of life measures.
Background: The catechol O methyltransferase inhibitor entacaponeacts by exte nding the elimination half life of levodopaand is currently approved as an adju nct to levodopa for thetreatment of patients with Parkinson disease (PD) with mo torfluctuations. Objective: To determine if the addition of entacapone administr ation provides benefit to levodopa treated PD patients who have a stable respon se to levodopa and do notexperience motor complications. Design: Prospective, do ubleblind,placebo controlled trial. Setting: Outpatient multicenter study. Pati ents: Female and male patients 30 years or older with idiopathic PD receiving st able doses of levodopa or carbidopa with or without other dopaminergic therapies and who did not experience motor fluctuations were eligible for the study. Main Outcome Measures: Parkinsonian function and quality of life. Results: The addit ion of entacapone did not improve motor scores on the Unified Parkinsons Disea se Rating Scale in levodopa treated PD patients who did not experience motor fl uctuations. The mean ±SE adjusted change between baseline and final treatment v isitwas -0.9±0.35 in the entacapone group and -0.8 ±0.35 in the placebo grou p (P = .83). Significant improvement with entacapone treatment was detected in s everal quality of life measures, including the Parkinson Disease Questionnaire 39, the 36 item Short Form Health Survey, the Parkinsons Symptom Inventory, and investigator and subject Clinical Global Assessments. The drug was well tolerated by patients in this population . Conclusions: The catechol Omethyltransferase inhibitor entacapone, used as an adjunct to levodopa in PD patients who do not experience motor fluctuations, doe s not improve Unified Parkinsons Disease Rating Scale motor scores but does im prove a variety of quality of life measures.
出处
《世界核心医学期刊文摘（神经病学分册）》
2005年第2期61-62,共2页
Digest of the World Core Medical Journals:Clinical Neurology
